Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots.

Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and a course that is unpredictable. Pulmonary hypertension may complicate the course of IPF and potentially impact prognosis. There are multiple factors that might influence the onset and severity of pulmonary hypertension in IPF. The relationship between the physiologic and pathobiologic manifestations of the progressive fibrotic process and interceding pulmonary hypertension has not been well defined. This article serves to explore these relationships and to hypothesize about the possible linkage between these entities. From a prognostic standpoint, recent evidence suggests this to be important to assess for pulmonary hypertension in patients with IPF. The appropriate triggers for evaluating for pulmonary hypertension and the best method of detection require further study. Despite the relative ease of noninvasive methods, such as echocardiography, right-heart catheterization remains the best diagnostic test. The appeal of pulmonary hypertension in IPF is that it may be an enticing therapeutic target in a disease that otherwise does not have any proven effective therapies. Which agent(s) might be useful and when they should be implemented mandate the appropriate studies being performed. Some of the data presented in this article have previously been reported in abstract form only.

[1]  A. Zaiman,et al.  Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[2]  G. Raghu,et al.  Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. , 2005, Chest.

[3]  B. Urban,et al.  Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. , 2003, Chest.

[4]  W. Seeger,et al.  Imatinib for the treatment of pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[5]  G. Raghu,et al.  The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis , 2005, European Respiratory Journal.

[6]  P. Hasleton,et al.  Angiogenic cytokines in patients with idiopathic interstitial pneumonia , 2004, Thorax.

[7]  S. Nathan,et al.  Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. , 2006, Chest.

[8]  A. Pardo,et al.  Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.

[9]  M. Vogeser,et al.  Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. , 2004, American journal of respiratory and critical care medicine.

[10]  F. Martinez,et al.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[11]  T. Oury,et al.  Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. , 2005, American journal of respiratory and critical care medicine.

[12]  R. Budhiraja,et al.  Endothelial Dysfunction in Pulmonary Hypertension , 2004, Circulation.

[13]  A. Nicholson,et al.  Interstitial vascularity in fibrosing alveolitis. , 2003, American journal of respiratory and critical care medicine.

[14]  M. Sheppard,et al.  Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis , 1993, The Lancet.

[15]  J. Tooze,et al.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. , 2001, American journal of respiratory and critical care medicine.

[16]  F. Martinez,et al.  Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[17]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[18]  R. Homer,et al.  Idiopathic pulmonary fibrosis: new insights into pathogenesis. , 2004, Clinics in chest medicine.

[19]  M. Sutton,et al.  Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. , 2003, American journal of respiratory and critical care medicine.

[20]  B. Corrin,et al.  Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. , 1997, American journal of respiratory cell and molecular biology.

[21]  W. Seeger,et al.  Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. , 1999, American journal of respiratory and critical care medicine.

[22]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[23]  S. Nathan,et al.  The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. , 2006, Respiratory medicine.

[24]  S. Nathan,et al.  PULMONARY HYPERTENSION IN IDIOPATHIC PULMONARY FIBROSIS: EPIDEMIOLOGY AND CLINICAL CORRELATES , 2005 .

[25]  K. Brown,et al.  Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. , 2004, American journal of respiratory and critical care medicine.

[26]  M. Kolb,et al.  Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls. , 2006, Proceedings of the American Thoracic Society.

[27]  P. Pellikka,et al.  Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. , 2004, Chest.

[28]  Takashi Suzuki,et al.  Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. , 2004, American journal of respiratory and critical care medicine.

[29]  N. Kaminski,et al.  Abnormal vascular phenotypes in patients with idiopathic pulmonary fibrosis and secondary pulmonary hypertension. , 2005, Chest.

[30]  N. Voelkel,et al.  5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.

[31]  H. Collard,et al.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[32]  I. Noth,et al.  Effects of Interferon-γ 1b on Biomarker Expression in Patients with Idiopathic Pulmonary Fibrosis , 2004 .

[33]  K P Offord,et al.  Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. , 1998, American journal of respiratory and critical care medicine.

[34]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[35]  M. Peters-Golden,et al.  Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. , 2005, Clinical science.

[36]  W. Seeger,et al.  Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.

[37]  F. Martinez,et al.  The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis , 2005, Annals of Internal Medicine.

[38]  M. Burdick,et al.  CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. , 2005, American journal of respiratory and critical care medicine.

[39]  T. Schaberg,et al.  Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? , 1997, Chest.

[40]  M. Bartels,et al.  Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. , 2005, Respiratory medicine.

[41]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[42]  E. Weitzenblum,et al.  Pulmonary hemodynamics in idiopathic pulmonary fibrosis and other interstitial pulmonary diseases. , 1983, Respiration; international review of thoracic diseases.

[43]  F. Martinez,et al.  Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. , 2006, American journal of respiratory and critical care medicine.

[44]  J. Behr,et al.  Brain natriuretic peptide is a prognostic parameter in chronic lung disease. , 2006, American journal of respiratory and critical care medicine.

[45]  S. Nathan,et al.  SERIAL MEASURES OF PULMONARY ARTERY PRESSURES IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS , 2005 .

[46]  S. Kimmel,et al.  Association between pulmonary fibrosis and coronary artery disease. , 2004, Archives of internal medicine.

[47]  P. Hopewell,et al.  Advances in the diagnosis and treatment of tuberculosis. , 2006, Proceedings of the American Thoracic Society.

[48]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[49]  F. D'Ovidio,et al.  Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.